Bausch + Lomb said a Phase 2 trial of BL1332, a treatment for pain following photorefractive keratectomy, did not meet its primary endpoint: a statistically significant reduction in pain intensity 24 hours after surgery.
November 20, 2026, 01:43 AM 103 0
Patients who received BL1332 showed numerically greater pain relief across the analysis 72 hours after surgery, the eye-health company said. The treatment was well tolerated.
Bausch + Lomb is completing its analysis of the data and plans to discuss the findings with the Food and Drug Administration, including potential plans for a Phase 3 trial.
Comments (0)
No comments yet. Be the first!